Sisram MedicalSRAMF 60 EBITDA Margin % is 9.29% as of Dec. 2025, which is 49% below its 10-year median of 18.21. GuruFocus rates SRAMF with a GF Score™ of 60/100 and a GF Value™ of $0.95 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sisram Medical ranks better than 52.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sisram Medical's EBITDA for the
six
months ended in Dec. 2025 was $18.6 Mil. Sisram Medical's Revenue for the
six
months ended in Dec. 2025 was $199.9 Mil. Therefore, Sisram Medical's EBITDA margin for the quarter that ended in Dec. 2025 was 9.29%.
Sisram Medical (OTCPK:SRAMF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sisram Medical EBITDA Margin % Related Terms
Sisram Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sisram Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRAMF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Sisram Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sisram Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical (SRAMF) has a EBITDA Margin % of 9.29% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sisram Medical and its competitors. This is 49% below median its historical median of 18.21. Over the past decade, Sisram Medical's EBITDA Margin % has ranged from 8.70 to 20.68. According to the industry distribution chart, Sisram Medical ranks #387 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 47.4%.
Is Sisram Medical's EBITDA Margin % too high?
Sisram Medical's current EBITDA Margin % of 9.29% is 49% below median its 10-year median of 18.21. Over the past 10 years, this metric has ranged from a low of 8.70 to a high of 20.68. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Sisram Medical's value of 9.29% is 24.3% above this industry median. Based on the distribution chart, Sisram Medical ranks #387 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sisram Medical has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #387 out of 816 companies for EBITDA Margin %. This puts Sisram Medical in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Sisram Medical's value of 9.29% is 24.3% above this benchmark. Historically, Sisram Medical's own EBITDA Margin % has ranged from 8.70 to 20.68 over the past decade. While the company's 10-year median is 18.21 vs. the industry median of 7.48, Sisram Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current EBITDA Margin % of 9.29% is 24.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current EBITDA Margin % is 9.29%, which is 49% below median its own 10-year median of 18.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.95, compared to a current price of $0.44 — trading 53.9% below its estimated fair value. The current EBITDA Margin % is 9.29%, which is 49% below median its 10-year median of 18.21 and 24.3% above the Medical Devices & Instruments industry median of 7.48. Sisram Medical's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current EBITDA Margin % is 9.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 53.9% below its estimated GF Value™ of $0.95.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
EBITDA Margin %: 9.29% (49% below median its 10-year median of 18.21)
GF Value™: $0.95 vs. price of $0.44 (53.9% below fair value)
Industry Position: 24.3% above the Medical Devices & Instruments median (#387 of 816)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
60GF Score
Get the complete analysis for SRAMF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
